Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Masini · SciRah

Researcher profile · Semantic Scholar

C. Masini

Share profile

C. Masini — researcher profile on SciRah

h-index: 25
Works: 137
Citations: 1,975

Most-cited papers

Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging
V. Iotti, S. Ravaioli, Rita Vacondio, C. Coriani +14 more
2017Breast Cancer Research140 citations Open access
Semantic Scholar
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
C. Sternberg, Y. Loriot, N. James, E. Choy +16 more
2019European Urology129 citations Open access
Semantic Scholar
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
S. Salvi, V. Casadio, V. Conteduca, S. Burgio +9 more
2015British Journal of Cancer124 citations Open access
Semantic Scholar
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
C. Masini, C. Iotti, U. de Giorgi, R. Bellia +20 more
2021European Urology104 citations Open access
Semantic Scholar
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
S. E. Rebuzzi, A. Signori, G. Banna, M. Maruzzo +41 more
2021Therapeutic Advances in Medical Oncology99 citations Open access
Semantic Scholar
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
G. Fornarini, S. E. Rebuzzi, G. Banna, F. Calabrò +16 more
2021ESMO Open59 citations Open access
Semantic Scholar
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer
C. Catania, M. Maur, R. Berardi, A. Rocca +15 more
2015Cell Adhesion & Migration58 citations Open access
Semantic Scholar
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
M. Santoni, A. Conti, C. Porta, G. Procopio +27 more
2015Journal of Urology58 citations
Semantic Scholar
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
G. Procopio, M. Claps, C. Pircher, L. Porcu +18 more
2022Tumori53 citations Open access
Semantic Scholar
First‐Line PAzopanib in NOn–clear‐cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study
S. Buti, M. Bersanelli, F. Maines, G. Facchini +16 more
2017Clinical Genitourinary Cancer53 citations
Semantic Scholar
Safety and Efficacy of Cabozantinib in Metastatic Renal‐Cell Carcinoma: Real‐World Data From an Italian Managed Access Program
G. Procopio, M. Prisciandaro, R. Iacovelli, E. Cortesi +29 more
2018Clinical Genitourinary Cancer41 citations
Semantic Scholar
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
O. Caffo, V. Zagonel, C. Baldessari, A. Berruti +16 more
2020Annals of Oncology35 citations Open access
Semantic Scholar
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
R. Iacovelli, C. Ciccarese, G. Facchini, M. Milella +20 more
2020Targeted oncology33 citations
Semantic Scholar
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
R. Iacovelli, U. de Giorgi, L. Galli, P. Zucali +19 more
2018Clinical Genitourinary Cancer32 citations
Semantic Scholar
Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial
C. Sternberg, F. Calabrò, S. Bracarda, G. Cartenì +17 more
2015Oncology32 citations
Semantic Scholar
Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study.
C. Masini, C. Iotti, U. de Giorgi, R. Bellia +15 more
202029 citations
Semantic Scholar
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
U. de Giorgi, E. Scarpi, C. Sacco, M. Aieta +15 more
2014Clinical Genitourinary Cancer29 citations
Semantic Scholar
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
M. Santoni, D. Heng, S. Bracarda, G. Procopio +45 more
2019Cancers28 citations Open access
Semantic Scholar
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
S. Buti, M. Bersanelli, A. Viansone, A. Leonetti +16 more
2019Cancer Treatment and Research Communications26 citations Open access
Semantic Scholar
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
M. Vitale, S. Scagliarini, L. Galli, S. Pignata +17 more
2018PLoS ONE25 citations Open access
Semantic Scholar
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
U. de Giorgi, K. Rihawi, M. Aieta, G. Lo Re +15 more
2014Journal of Geriatric Oncology24 citations
Semantic Scholar
Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
N. Normanno, A. De Luca, R. E. Abate, A. Morabito +15 more
2023European Journal of Cancer23 citations Open access
Semantic Scholar
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
F. Vignani, R. Tambaro, U. de Giorgi, P. Giannatempo +20 more
2022European Urology21 citations Open access
Semantic Scholar
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer
O. Caffo, D. Gasparro, G. Di Lorenzo, A. D. Volta +21 more
2020European Journal of Cancer20 citations Open access
Semantic Scholar
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.
M. Vitale, S. Pipitone, M. Venturelli, C. Baldessari +24 more
2020Clinical Genitourinary Cancer19 citations Open access
Semantic Scholar
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
A. Leonetti, M. Bersanelli, B. Castagneto, C. Masini +3 more
2016Clinical Genitourinary Cancer17 citations
Semantic Scholar
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
R. Iacovelli, C. Ciccarese, M. Brunelli, N. Battelli +17 more
2022Annals of Oncology15 citations Open access
Semantic Scholar
Safety and Efficacy of Pazopanib in First‐Line Metastatic Renal‐Cell Carcinoma With or Without Renal Failure: CORE‐URO‐01 Study
C. Masini, M. Vitale, M. Maruzzo, G. Procopio +12 more
2019Clinical Genitourinary Cancer12 citations
Semantic Scholar
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
R. Iacovelli, Maria Cossu Rocca, L. Galli, U. de Giorgi +18 more
2017Urologic oncology11 citations
Semantic Scholar
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223
O. Caffo, V. Frantellizzi, M. Tucci, L. Galli +17 more
2020European Journal of Nuclear Medicine and Molecular Imaging10 citations
Semantic Scholar
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)
Maria Giuseppa Vitale, S. Bracarda, L. Cosmai, E. Crocetti +20 more
2019Tumori10 citations
Semantic Scholar
Results of an Italian CORE-IMMUNO study: Safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs).
C. Masini, A. Berselli, A. Romagnani, C. Bonelli +10 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis.
A. Guida, C. Masini, M. Milella, G. Di Lorenzo +8 more
2015Future Oncology9 citations Open access
Semantic Scholar
The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
R. Iacovelli, L. Galli, U. de Giorgi, C. Porta +19 more
2019Urologic oncology8 citations
Semantic Scholar
Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
F. Vignani, R. Tambaro, U. de Giorgi, P. Giannatempo +16 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
S. Bianchi, A. Mosca, Alberto Dalla Volta, V. Prati +20 more
2021European Journal of Cancer7 citations Open access
Semantic Scholar
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.
Cora N. Sternberg, Y. Loriot, E. Choy, D. Castellano +18 more
2024European Urology Focus6 citations Open access
Semantic Scholar
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication
S. Buti, U. Basso, D. Giannarelli, U. de Giorgi +28 more
2022Journal of immunotherapy6 citations Open access
Semantic Scholar
NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).
C. Masini, C. Iotti, P. Ciammella, Roberta Gnoni +16 more
20186 citations
Semantic Scholar
First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.
S. Buti, M. Bersanelli, F. Maines, G. Facchini +15 more
20166 citations Open access
Semantic Scholar
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.
R. Iacovelli, D. Santini, M. Rizzo, A. Felici +7 more
2015Canadian Urological Association journal = Journal de l'Association des urologues du Canada6 citations Open access
Semantic Scholar
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients
S. Buti, Alessandro Olivari, C. Masini, D. Bimbatti +19 more
2024Therapeutic Advances in Urology5 citations Open access
Semantic Scholar
A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).
G. Procopio, M. Claps, C. Pircher, L. Porcu +16 more
20215 citations
Semantic Scholar
Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
G. Bonfante, E. Fantinel, C. Masini, F. Bergamaschi +2 more
2020Urology Case Reports5 citations Open access
Semantic Scholar
The Impact of COVID-19 on New Kidney Cancer Diagnosis: Stage and Treatment in Northern Italy
L. Mangone, F. Marinelli, G. Bonfante, I. Bisceglia +4 more
2023International Journal of Environmental Research and Public Health4 citations Open access
Semantic Scholar
First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial.
R. Iacovelli, C. Ciccarese, M. Brunelli, N. Battelli +16 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
A. Sbrana, E. Biasco, F. Paolieri, E. Palesandro +10 more
2018Anticancer Research4 citations Open access
Semantic Scholar
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
V. Murianni, A. Signori, S. Buti, S. E. Rebuzzi +34 more
2024Frontiers in Oncology3 citations Open access
Semantic Scholar
Trends in Incidence and Mortality of Kidney Cancer in a Northern Italian Province: An Update to 2020
L. Mangone, F. Marinelli, L. Tarantini, C. Masini +4 more
2022Biology3 citations Open access
Semantic Scholar
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak
M. Bersanelli, S. Buti, M. Rizzo, A. Cortellini +26 more
2021Therapeutic Advances in Urology3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

U. de Giorgi×28
Invite
U. de Giorgi — researcher profile on SciRah
S. Buti×25
Invite
S. Buti — researcher profile on SciRah
G. Procopio×21
Invite
G. Procopio — researcher profile on SciRah
R. Iacovelli×19
Invite
R. Iacovelli — researcher profile on SciRah

×19

Invite

G. Fornarini — researcher profile on SciRah

Invite

L. Galli — researcher profile on SciRah

Invite

M. Vitale — researcher profile on SciRah

Invite

F. Nolè — researcher profile on SciRah

Invite

F. Morelli — researcher profile on SciRah

Invite

D. Santini — researcher profile on SciRah

Invite

M. Santoni — researcher profile on SciRah

Invite

F. Atzori — researcher profile on SciRah